{"protocolSection": {"identificationModule": {"nctId": "NCT01217073", "orgStudyIdInfo": {"id": "3102-006"}, "secondaryIdInfos": [{"id": "2010-022193-13", "type": "EUDRACT_NUMBER"}, {"id": "2011-000656-42", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)", "officialTitle": "A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-10-08", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2012-01-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-04-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-10-06", "studyFirstSubmitQcDate": "2010-10-06", "studyFirstPostDateStruct": {"date": "2010-10-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-09-29", "resultsFirstSubmitQcDate": "2015-09-29", "resultsFirstPostDateStruct": {"date": "2015-10-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-08-08", "lastUpdatePostDateStruct": {"date": "2018-09-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the hypothesis that treatment with study medication (omarigliptin; MK-3102) provides greater reduction in A1C Hemoglobin (a marker of diabetic severity) compared with placebo, after 12 weeks of treatment. The study will evaluate 5 different doses of omarigliptin to identify which dose is the most effective in the treatment of type 2 diabetes.", "detailedDescription": "MK-3102-006-Ext 1 added a 66-week extension to the base study (MK-3102 P006) to assess the long-term safety and tolerability of omarigliptin. To be eligible for the extension, participants must complete the double-blind base study, must have had at least a 75% compliance with study drug during the base study and can not meet any of the criteria for discontinuation. Participants randomized to placebo in the base study will be switched in a blinded manner to pioglitazone 30 mg once daily, in the extension study prior to implementation of amendment P006-13. Once amendment P006-13 has been IRB/IEC approved and blinded metformin drug supply is available at the site, participants will be switched from pioglitazone to metformin, starting at 500 mg once daily and titrated up to 1000 mg twice daily. Participants with a contraindication to metformin will be discontinued from the study. Participants randomized to 0.25 mg, 1 mg, 3 mg, and 10 mg of omarigliptin in the base study will be switched to omarigliptin 25 mg; those randomized to 25 mg of omarigliptin in the base study will continue on the same dose in the extension study. After the clinical dose of omarigliptin selected for further development has been identified based upon the results of the base study, all participants randomized to omarigliptin will be switched to the identified clinical dose."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 685, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Omarigliptin 0.25 mg (Base)", "type": "EXPERIMENTAL", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base)", "interventionNames": ["Drug: Omarigliptin"]}, {"label": "Omarigliptin 1 mg (Base)", "type": "EXPERIMENTAL", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (Base)", "interventionNames": ["Drug: Omarigliptin"]}, {"label": "Omarigliptin 3 mg (Base)", "type": "EXPERIMENTAL", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (Base)", "interventionNames": ["Drug: Omarigliptin"]}, {"label": "Omarigliptin 10 mg (Base)", "type": "EXPERIMENTAL", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (Base)", "interventionNames": ["Drug: Omarigliptin"]}, {"label": "Omarigliptin 25 mg (Base)", "type": "EXPERIMENTAL", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (Base)", "interventionNames": ["Drug: Omarigliptin"]}, {"label": "Placebo (Base)", "type": "PLACEBO_COMPARATOR", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (Base)", "interventionNames": ["Drug: Placebo to omarigliptin"]}, {"label": "Pooled omarigliptin (Extension)", "type": "EXPERIMENTAL", "description": "Participants who received omarigliptin during the base study, received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (Extension).", "interventionNames": ["Drug: Omarigliptin", "Drug: Placebo to metformin"]}, {"label": "Placebo/Metformin", "type": "ACTIVE_COMPARATOR", "description": "Participants who received matching placebo to omarigliptin during the base period, received pioglitazone administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (extension period). Note: A protocol amendment removed pioglitazone during the extension period. Participants discontinued pioglitazone and switched to blinded metformin. Participants who were previously rescued with open-label metformin during the base period continued in the extension period on open-label metformin.", "interventionNames": ["Drug: Placebo to omarigliptin", "Drug: Pioglitazone", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Omarigliptin", "description": "Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.", "armGroupLabels": ["Omarigliptin 0.25 mg (Base)", "Omarigliptin 1 mg (Base)", "Omarigliptin 10 mg (Base)", "Omarigliptin 25 mg (Base)", "Omarigliptin 3 mg (Base)", "Pooled omarigliptin (Extension)"]}, {"type": "DRUG", "name": "Placebo to omarigliptin", "description": "Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.", "armGroupLabels": ["Placebo (Base)", "Placebo/Metformin"]}, {"type": "DRUG", "name": "Pioglitazone", "description": "Pioglitazone 15 mg oral tablet or capsule administered once daily", "armGroupLabels": ["Placebo/Metformin"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin 500 mg oral tablet administered once or twice daily", "armGroupLabels": ["Placebo/Metformin"]}, {"type": "DRUG", "name": "Placebo to metformin", "description": "Matching placebo to metformin oral tablet administered once daily", "armGroupLabels": ["Pooled omarigliptin (Extension)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Plasma A1C Levels at Week 12", "description": "A1C levels were measured as a percent. Change from baseline was calculated by subtracting the baseline level from the Week 12 level.", "timeFrame": "Baseline (Week 0) and Week 12"}, {"measure": "Percentage of Participants Who Experienced at Least One Adverse Event During the Base Period", "description": "An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.", "timeFrame": "Up to 16 weeks (including 28 days following the last dose of study drug)"}, {"measure": "Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During the 12-week Base Period", "description": "An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.", "timeFrame": "Up to 12 weeks"}, {"measure": "Percentage of Participants Who Experienced at Least One Adverse Event During the 66-week Extension Period", "description": "An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.", "timeFrame": "Up to 70 Weeks (Weeks 12 to 78 plus 4-week follow-up period)"}, {"measure": "Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event During the 66-week Extension Period", "description": "An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.", "timeFrame": "Up to 66 weeks (Weeks 12 to 78)"}], "secondaryOutcomes": [{"measure": "Change From Baseline in 2 Hour-post-meal Glucose (2h-PMG) Levels at Week 12", "description": "Change from baseline was calculated by subtracting the baseline level from the Week 12 level.", "timeFrame": "Baseline (Week 0) and Week 12"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) Levels at Week 12", "description": "Change from baseline was calculated by subtracting the baseline level from the Week 12 level.", "timeFrame": "Baseline (Week 0) and Week 12"}, {"measure": "Mean Plasma A1C Level at Baseline of the Extension Period", "description": "A1C levels were measured as a percent at baseline (Week 0) for participants who entered the extension period.", "timeFrame": "Baseline (Week 0)"}, {"measure": "Change From Baseline in Plasma A1C Levels at Week 78", "description": "A1C levels were measured as a percent. Change from baseline was calculated by subtracting the baseline level from the Week 78 level.", "timeFrame": "Baseline (Week 0) and Week 78"}, {"measure": "Mean 2h-PMG Level at Baseline of the Extension Period", "description": "Plasma 2h-PMG levels were measured at baseline (Week 0) for participants who entered the extension period.", "timeFrame": "Baseline (Week 0)"}, {"measure": "Change From Baseline in 2h-PMG at Week 78", "description": "Change from baseline was calculated by subtracting the baseline level from the Week 78 level.", "timeFrame": "Baseline (Week 0) and Week 78"}, {"measure": "Mean FPG Level at Baseline of the Extension Period", "description": "Plasma FPG levels were measured at baseline (Week 0) for particiapnts who entered the extension period.", "timeFrame": "Baseline (Week 0)"}, {"measure": "Change From Baseline in FPG Levels at Week 78", "description": "Change from baseline was calculated by subtracting the baseline level from the Week 78 level.", "timeFrame": "Baseline (Week 0) and Week 78"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nThe prospective participant must meet, at least, all of the criteria below (among others determined by the study staff) to be eligible for study participation.\n\nThe participant:\n\n* Has type 2 diabetes mellitus and is between 18 and 70 years of age; for Japan, 20 to 70 years of age;\n* Has a body mass index (BMI) \\> 20 kg/m\\^2 and \\< 43 kg/m\\^2; for Japan: BMI \\>18 kg/m\\^2 and \\<43 kg/m\\^2;\n* Is currently not on an antihyperglycemic agent (AHA) medication (off for \u2265 14 weeks) or is on oral AHA therapy but has inadequate glycemic control;\n* Is a male, or a female who is highly unlikely to conceive.\n\nExclusion Criteria:\n\nIf the prospective participant meets any of the criteria below (among others determined by the study staff) they will NOT be eligible for study participation.\n\nThe participant:\n\n* Has a history of type 1 diabetes mellitus or a history of ketoacidosis;\n* Is on a weight loss program or has started a weight loss medication within the prior 8 weeks;\n* Has required insulin therapy within 14 weeks prior to signing informed consent;\n* Has a medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic active hepatitis B or C, cirrhosis, or symptomatic gallbladder disease;\n* Has congestive heart failure or has new or worsening signs or symptoms of coronary heart disease;\n* Had any of the following disorders within the past 3 months: acute coronary syndrome, coronary artery intervention, stroke or transient ischemic neurological disorder;\n* Has a history of malignancy or clinically important hematological disorder", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "26310692", "type": "RESULT", "citation": "Sheu WH, Gantz I, Chen M, Suryawanshi S, Mirza A, Goldstein BJ, Kaufman KD, Engel SS. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes. Diabetes Care. 2015 Nov;38(11):2106-14. doi: 10.2337/dc15-0109. Epub 2015 Aug 26."}], "availIpds": [{"type": "CSR Synopsis", "url": "http://www.merck.com/clinical-trials/study.html?id=3102-006&kw=3102-006&tab=access"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Omarigliptin 0.25 mg (Base)", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (base period)"}, {"id": "FG001", "title": "Omarigliptin 1 mg (Base)", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (base period)"}, {"id": "FG002", "title": "Omarigliptin 3 mg (Base)", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (base period)"}, {"id": "FG003", "title": "Omarigliptin 10 mg (Base)", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (base period)"}, {"id": "FG004", "title": "Omarigliptin 25 mg (Base)", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (base period)"}, {"id": "FG005", "title": "Placebo (Base)", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (base period)"}, {"id": "FG006", "title": "Pooled Omarigliptin (Extension)", "description": "Participants received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (extension period)"}, {"id": "FG007", "title": "Placebo/Metformin (Extension)", "description": "Participants who received matching placebo to omarigliptin during the base study, received pioglitazone 30 mg once daily and matching placebo to omarigliptin once weekly for 66 weeks (Extension period). Participants were switched from pioglitazone to metformin starting at 500 mg once daily and titrated up to 1000 mg twice a day"}], "periods": [{"title": "Base Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "113"}, {"groupId": "FG001", "numSubjects": "115"}, {"groupId": "FG002", "numSubjects": "114"}, {"groupId": "FG003", "numSubjects": "115"}, {"groupId": "FG004", "numSubjects": "114"}, {"groupId": "FG005", "numSubjects": "114"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "106"}, {"groupId": "FG001", "numSubjects": "110"}, {"groupId": "FG002", "numSubjects": "107"}, {"groupId": "FG003", "numSubjects": "113"}, {"groupId": "FG004", "numSubjects": "99"}, {"groupId": "FG005", "numSubjects": "105"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "15"}, {"groupId": "FG005", "numSubjects": "9"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Alanine aminotransferase (ALT)/AST", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Excluded medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "2"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "5"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}]}, {"title": "Extension Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "405"}, {"groupId": "FG007", "numSubjects": "80"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "314"}, {"groupId": "FG007", "numSubjects": "60"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "91"}, {"groupId": "FG007", "numSubjects": "20"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "19"}, {"groupId": "FG007", "numSubjects": "5"}]}, {"type": "ALT/AST", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "2"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Contraindication to study medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Creatinine/eGFR", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "11"}, {"groupId": "FG007", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Excluded medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "2"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "9"}, {"groupId": "FG007", "numSubjects": "1"}]}, {"type": "Non-compliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "2"}, {"groupId": "FG007", "numSubjects": "1"}]}, {"type": "Site discontinued study participation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "7"}, {"groupId": "FG007", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "30"}, {"groupId": "FG007", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Population includes all participants randomized during the base period. The extension period only included participants who completed the base period and consented to enter the extension period.", "groups": [{"id": "BG000", "title": "Omarigliptin 0.25 mg (Base)", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (base period)"}, {"id": "BG001", "title": "Omarigliptin 1 mg (Base)", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (base period)"}, {"id": "BG002", "title": "Omarigliptin 3 mg (Base)", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (base period)"}, {"id": "BG003", "title": "Omarigliptin 10 mg (Base)", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (base period)"}, {"id": "BG004", "title": "Omarigliptin 25 mg (Base)", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (base period)"}, {"id": "BG005", "title": "Placebo (Base)", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (base period)"}, {"id": "BG006", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "113"}, {"groupId": "BG001", "value": "115"}, {"groupId": "BG002", "value": "114"}, {"groupId": "BG003", "value": "115"}, {"groupId": "BG004", "value": "114"}, {"groupId": "BG005", "value": "114"}, {"groupId": "BG006", "value": "685"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.3", "spread": "8.9"}, {"groupId": "BG001", "value": "55.7", "spread": "8.5"}, {"groupId": "BG002", "value": "55.3", "spread": "8.5"}, {"groupId": "BG003", "value": "54.4", "spread": "10.0"}, {"groupId": "BG004", "value": "55.1", "spread": "8.5"}, {"groupId": "BG005", "value": "55.9", "spread": "8.4"}, {"groupId": "BG006", "value": "55.1", "spread": "8.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "49"}, {"groupId": "BG003", "value": "59"}, {"groupId": "BG004", "value": "45"}, {"groupId": "BG005", "value": "49"}, {"groupId": "BG006", "value": "298"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "65"}, {"groupId": "BG001", "value": "67"}, {"groupId": "BG002", "value": "65"}, {"groupId": "BG003", "value": "56"}, {"groupId": "BG004", "value": "69"}, {"groupId": "BG005", "value": "65"}, {"groupId": "BG006", "value": "387"}]}]}]}, {"title": "Hemoglobin A1c (A1C)", "description": "Participants with data: Omariglptin 0.25 mg, n=113; Omariglptin 1 mg, n=115; Omariglptin 3 mg, n=114; Omariglptin 10 mg, n=115; Omariglptin 25 mg, n=113; Placebo, n=113; Total, n=683", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.1", "spread": "0.9"}, {"groupId": "BG001", "value": "8.0", "spread": "0.9"}, {"groupId": "BG002", "value": "7.9", "spread": "0.9"}, {"groupId": "BG003", "value": "8.0", "spread": "0.9"}, {"groupId": "BG004", "value": "8.1", "spread": "1.0"}, {"groupId": "BG005", "value": "8.1", "spread": "0.9"}, {"groupId": "BG006", "value": "8.1", "spread": "0.9"}]}]}]}, {"title": "2-hour post meal glucose (2-hr PMG)", "description": "Participants with data: Omariglptin 0.25 mg, n=111; Omariglptin 1 mg, n=113; Omariglptin 3 mg, n=113; Omariglptin 10 mg, n=112; Omariglptin 25 mg, n=111; Placebo, n=110; Total, n=670", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "229.4", "spread": "63.7"}, {"groupId": "BG001", "value": "229.3", "spread": "64.5"}, {"groupId": "BG002", "value": "234.7", "spread": "81.7"}, {"groupId": "BG003", "value": "231.6", "spread": "72.3"}, {"groupId": "BG004", "value": "245.3", "spread": "82.7"}, {"groupId": "BG005", "value": "241.4", "spread": "72.2"}, {"groupId": "BG006", "value": "235.2", "spread": "73.2"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "description": "Participants with data: Omariglptin 0.25 mg, n=113; Omariglptin 1 mg, n=115; Omariglptin 3 mg, n=114; Omariglptin 10 mg, n=115; Omariglptin 25 mg, n=114; Placebo, n=113; Total, n=684", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "170.3", "spread": "45.3"}, {"groupId": "BG001", "value": "169.4", "spread": "42.4"}, {"groupId": "BG002", "value": "169.0", "spread": "42.6"}, {"groupId": "BG003", "value": "166.8", "spread": "37.6"}, {"groupId": "BG004", "value": "173.9", "spread": "47.6"}, {"groupId": "BG005", "value": "171.9", "spread": "42.8"}, {"groupId": "BG006", "value": "170.2", "spread": "43.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Plasma A1C Levels at Week 12", "description": "A1C levels were measured as a percent. Change from baseline was calculated by subtracting the baseline level from the Week 12 level.", "populationDescription": "Full analysis set defined as all randomized participants who received at least one dose of study treatment and had a baseline measurement or a post-randomization measurement for the analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline (Week 0) and Week 12", "groups": [{"id": "OG000", "title": "Omarigliptin 0.25 mg (Base)", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG001", "title": "Omarigliptin 1 mg (Base)", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG002", "title": "Omarigliptin 3 mg (Base)", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG003", "title": "Omarigliptin 10 mg (Base)", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG004", "title": "Omarigliptin 25 mg (Base)", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG005", "title": "Placebo (Base)", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (base period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "114"}, {"groupId": "OG003", "value": "115"}, {"groupId": "OG004", "value": "114"}, {"groupId": "OG005", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.14", "lowerLimit": "-0.30", "upperLimit": "0.01"}, {"groupId": "OG001", "value": "-0.36", "lowerLimit": "-0.51", "upperLimit": "-0.20"}, {"groupId": "OG002", "value": "-0.35", "lowerLimit": "-0.50", "upperLimit": "-0.19"}, {"groupId": "OG003", "value": "-0.53", "lowerLimit": "-0.68", "upperLimit": "-0.38"}, {"groupId": "OG004", "value": "-0.57", "lowerLimit": "-0.73", "upperLimit": "-0.42"}, {"groupId": "OG005", "value": "0.14", "lowerLimit": "-0.01", "upperLimit": "0.29"}]}]}], "analyses": [{"groupIds": ["OG004", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-0.71", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.93", "ciUpperLimit": "-0.50"}, {"groupIds": ["OG003", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-0.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.88", "ciUpperLimit": "-0.45"}, {"groupIds": ["OG002", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-0.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.70", "ciUpperLimit": "-0.27"}, {"groupIds": ["OG001", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-0.50", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.71", "ciUpperLimit": "-0.28"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.012", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-0.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.50", "ciUpperLimit": "-0.06"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experienced at Least One Adverse Event During the Base Period", "description": "An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.", "populationDescription": "The all participants as treated population defined as all randomized participants who received at least one dose of study treatment. Participants were included in the treatment group corresponding to the study treatment they actually received during the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 16 weeks (including 28 days following the last dose of study drug)", "groups": [{"id": "OG000", "title": "Omarigliptin 0.25 mg (Base)", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG001", "title": "Omarigliptin 1 mg (Base)", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG002", "title": "Omarigliptin 3 mg (Base)", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG003", "title": "Omarigliptin 10 mg (Base)", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG004", "title": "Omarigliptin 25 mg (Base)", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG005", "title": "Placebo (Base)", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (base period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "114"}, {"groupId": "OG003", "value": "115"}, {"groupId": "OG004", "value": "114"}, {"groupId": "OG005", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "37.2"}, {"groupId": "OG001", "value": "43.5"}, {"groupId": "OG002", "value": "36.8"}, {"groupId": "OG003", "value": "36.5"}, {"groupId": "OG004", "value": "33.3"}, {"groupId": "OG005", "value": "31.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "6.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.2", "ciUpperLimit": "18.4"}, {"groupIds": ["OG001", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "12.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.1", "ciUpperLimit": "24.7"}, {"groupIds": ["OG002", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "5.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.5", "ciUpperLimit": "18.0"}, {"groupIds": ["OG003", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "5.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.8", "ciUpperLimit": "17.7"}, {"groupIds": ["OG004", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "2.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.8", "ciUpperLimit": "14.5"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During the 12-week Base Period", "description": "An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.", "populationDescription": "The all participants as treated population defined as all randomized participants who received at least one dose of study treatment. Participants were included in the treatment group corresponding to the study treatment they actually received during the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 12 weeks", "groups": [{"id": "OG000", "title": "Omarigliptin 0.25 mg (Base)", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG001", "title": "Omarigliptin 1 mg (Base)", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG002", "title": "Omarigliptin 3 mg (Base)", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG003", "title": "Omarigliptin 10 mg (Base)", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG004", "title": "Omarigliptin 25 mg (Base)", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG005", "title": "Placebo (Base)", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (base period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "114"}, {"groupId": "OG003", "value": "115"}, {"groupId": "OG004", "value": "114"}, {"groupId": "OG005", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0.9"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "3.5"}, {"groupId": "OG005", "value": "0.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "0.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.1", "ciUpperLimit": "4.1"}, {"groupIds": ["OG001", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "-0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.9", "ciUpperLimit": "2.4"}, {"groupIds": ["OG002", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "0.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.1", "ciUpperLimit": "4.0"}, {"groupIds": ["OG003", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "-0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.9", "ciUpperLimit": "2.4"}, {"groupIds": ["OG004", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "2.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.7", "ciUpperLimit": "7.9"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experienced at Least One Adverse Event During the 66-week Extension Period", "description": "An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.", "populationDescription": "Analysis population defined as all randomized participamts who received at least one dose of extension study treatment. Participants were included in the treatment group corresponding to the study treatment they actually received. Participants who received glycemic rescue during the base period were excluded from this analysis population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 70 Weeks (Weeks 12 to 78 plus 4-week follow-up period)", "groups": [{"id": "OG000", "title": "Pooled Omarigliptin (Extension)", "description": "Participants received omarigliptin 25 mg once weekly for 66 weeks (extension period)"}, {"id": "OG001", "title": "Placebo/Metformin (Extension)", "description": "Participants who received matching placebo to omarigliptin during the base study, received pioglitazone 30 mg once daily and matching placebo to omarigliptin once weekly for 66 weeks (Extension period). Participants were switched from pioglitazone to metformin starting at 500 mg once daily and titrated up to 1000 mg twice a day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "392"}, {"groupId": "OG001", "value": "76"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "66.8"}, {"groupId": "OG001", "value": "65.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percent", "paramValue": "1.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.8", "ciUpperLimit": "13.1"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event During the 66-week Extension Period", "description": "An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.", "populationDescription": "Analysis population defined as all randomized participants who received at least one dose of extension study treatment. Participants were included in the treatment group corresponding to the study treatment they actually received. Participants who received glycemic rescue during the base period were excluded from this analysis population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 66 weeks (Weeks 12 to 78)", "groups": [{"id": "OG000", "title": "Pooled Omarigliptin (Extension)", "description": "Participants received omarigliptin 25 mg once weekly for 66 weeks (extension period)"}, {"id": "OG001", "title": "Placebo/Metformin (Extension)", "description": "Participants who received matching placebo to omarigliptin during the base study, received pioglitazone 30 mg once daily and matching placebo to omarigliptin once weekly for 66 weeks (Extension period). Participants were switched from pioglitazone to metformin starting at 500 mg once daily and titrated up to 1000 mg twice a day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "392"}, {"groupId": "OG001", "value": "76"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.8"}, {"groupId": "OG001", "value": "5.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percent", "paramValue": "-1.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.1", "ciUpperLimit": "2.6"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2 Hour-post-meal Glucose (2h-PMG) Levels at Week 12", "description": "Change from baseline was calculated by subtracting the baseline level from the Week 12 level.", "populationDescription": "Full analysis set defined as all randomized participants who received at least one dose of study treatment and had a baseline measurement or a post-randomization measurement for the analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline (Week 0) and Week 12", "groups": [{"id": "OG000", "title": "Omarigliptin 0.25 mg (Base)", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG001", "title": "Omarigliptin 1 mg (Base)", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG002", "title": "Omarigliptin 3 mg (Base)", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG003", "title": "Omarigliptin 10 mg (Base)", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG004", "title": "Omarigliptin 25 mg (Base)", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG005", "title": "Placebo (Base)", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (base period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "113"}, {"groupId": "OG002", "value": "114"}, {"groupId": "OG003", "value": "114"}, {"groupId": "OG004", "value": "112"}, {"groupId": "OG005", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.3", "lowerLimit": "-21.5", "upperLimit": "-1.1"}, {"groupId": "OG001", "value": "-26.0", "lowerLimit": "-35.8", "upperLimit": "-16.2"}, {"groupId": "OG002", "value": "-27.5", "lowerLimit": "-37.3", "upperLimit": "-17.8"}, {"groupId": "OG003", "value": "-34.0", "lowerLimit": "-43.7", "upperLimit": "-24.3"}, {"groupId": "OG004", "value": "-37.3", "lowerLimit": "-47.6", "upperLimit": "-27.1"}, {"groupId": "OG005", "value": "7.5", "lowerLimit": "-2.6", "upperLimit": "17.7"}]}]}], "analyses": [{"groupIds": ["OG004", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-44.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-59.0", "ciUpperLimit": "-30.7"}, {"groupIds": ["OG003", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-41.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-55.3", "ciUpperLimit": "-27.8"}, {"groupIds": ["OG002", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-35.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-48.9", "ciUpperLimit": "-21.3"}, {"groupIds": ["OG001", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-33.5", "ciPctValue": "95", "ciLowerLimit": "-47.3", "ciUpperLimit": "-19.7"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.009", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-18.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-32.9", "ciUpperLimit": "-4.8"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) Levels at Week 12", "description": "Change from baseline was calculated by subtracting the baseline level from the Week 12 level.", "populationDescription": "Full analysis set defined as all randomized participants who received at least one dose of study treatment and had a baseline measurement or a post-randomization measurement for the analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline (Week 0) and Week 12", "groups": [{"id": "OG000", "title": "Omarigliptin 0.25 mg (Base)", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG001", "title": "Omarigliptin 1 mg (Base)", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG002", "title": "Omarigliptin 3 mg (Base)", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG003", "title": "Omarigliptin 10 mg (Base)", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG004", "title": "Omarigliptin 25 mg (Base)", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (base period)"}, {"id": "OG005", "title": "Placebo (Base)", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (base period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "114"}, {"groupId": "OG003", "value": "115"}, {"groupId": "OG004", "value": "114"}, {"groupId": "OG005", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.2", "lowerLimit": "-4.5", "upperLimit": "7.0"}, {"groupId": "OG001", "value": "-15.3", "lowerLimit": "-20.9", "upperLimit": "-9.7"}, {"groupId": "OG002", "value": "-10.6", "lowerLimit": "-16.3", "upperLimit": "-4.8"}, {"groupId": "OG003", "value": "-9.8", "lowerLimit": "-15.4", "upperLimit": "-4.2"}, {"groupId": "OG004", "value": "-17.7", "lowerLimit": "-23.5", "upperLimit": "-11.8"}, {"groupId": "OG005", "value": "3.7", "lowerLimit": "-2.0", "upperLimit": "9.4"}]}]}], "analyses": [{"groupIds": ["OG004", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-21.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-29.4", "ciUpperLimit": "-13.4"}, {"groupIds": ["OG003", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-13.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.3", "ciUpperLimit": "-5.7"}, {"groupIds": ["OG002", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-14.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-22.2", "ciUpperLimit": "-6.3"}, {"groupIds": ["OG001", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-19.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.9", "ciUpperLimit": "-11.2"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.539", "pValueComment": "With terms for treatment, prior AHA therapy status, geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status, with the constraint that the mean baseline is the same for all treatment groups.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in least squares mean", "paramValue": "-2.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.4", "ciUpperLimit": "5.5"}]}, {"type": "SECONDARY", "title": "Mean Plasma A1C Level at Baseline of the Extension Period", "description": "A1C levels were measured as a percent at baseline (Week 0) for participants who entered the extension period.", "populationDescription": "All participants who entered the extension period of the study with available A1C baseline data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "Baseline (Week 0)", "groups": [{"id": "OG000", "title": "Pooled Omarigliptin (Extension)", "description": "Participants received omarigliptin 25 mg once weekly for 66 weeks (extension period)"}, {"id": "OG001", "title": "Placebo/Metformin (Extension)", "description": "Participants who received matching placebo to omarigliptin during the base study, received pioglitazone 30 mg once daily and matching placebo to omarigliptin once weekly for 66 weeks (Extension period). Participants were switched from pioglitazone to metformin starting at 500 mg once daily and titrated up to 1000 mg twice a day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "404"}, {"groupId": "OG001", "value": "80"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.0", "spread": "0.9"}, {"groupId": "OG001", "value": "8.2", "spread": "0.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Plasma A1C Levels at Week 78", "description": "A1C levels were measured as a percent. Change from baseline was calculated by subtracting the baseline level from the Week 78 level.", "populationDescription": "Extension full analysis set population defined as all randomized participants who received at least one dose of extension study treatment, have baseline and at least one post-randomization observation for the analysis endpoint subsequent to at least one dose of extension study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline (Week 0) and Week 78", "groups": [{"id": "OG000", "title": "Omarigliptin 0.25 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG001", "title": "Omarigliptin 1 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG002", "title": "Omarigliptin 3 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG003", "title": "Omarigliptin 10 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG004", "title": "Omarigliptin 25 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG005", "title": "Placebo (Base)/Metformin (Extension)", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (Base) followed by pioglitazone 30 mg administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (Extension). Piogliatazone was removed by a protocol amendment and replaced with metformin starting dose 500 mg one daily up-titrated to 1000 mg twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "82"}, {"groupId": "OG004", "value": "70"}, {"groupId": "OG005", "value": "80"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.57", "lowerLimit": "-0.89", "upperLimit": "-0.25"}, {"groupId": "OG001", "value": "-0.55", "lowerLimit": "-0.85", "upperLimit": "-0.26"}, {"groupId": "OG002", "value": "-0.30", "lowerLimit": "-0.62", "upperLimit": "0.02"}, {"groupId": "OG003", "value": "-0.60", "lowerLimit": "-0.93", "upperLimit": "-0.28"}, {"groupId": "OG004", "value": "-0.46", "lowerLimit": "-0.80", "upperLimit": "-0.11"}, {"groupId": "OG005", "value": "-0.88", "lowerLimit": "-1.19", "upperLimit": "-0.57"}]}]}]}, {"type": "SECONDARY", "title": "Mean 2h-PMG Level at Baseline of the Extension Period", "description": "Plasma 2h-PMG levels were measured at baseline (Week 0) for participants who entered the extension period.", "populationDescription": "All participants who entered the extension period of the study with available 2h-PMG baseline data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline (Week 0)", "groups": [{"id": "OG000", "title": "Pooled Omarigliptin (Extension)", "description": "Participants received omarigliptin 25 mg once weekly for 66 weeks (extension period)"}, {"id": "OG001", "title": "Placebo/Metformin (Extension)", "description": "Participants who received matching placebo to omarigliptin during the base study, received pioglitazone 30 mg once daily and matching placebo to omarigliptin once weekly for 66 weeks (Extension period). Participants were switched from pioglitazone to metformin starting at 500 mg once daily and titrated up to 1000 mg twice a day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "402"}, {"groupId": "OG001", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "232.8", "spread": "69.5"}, {"groupId": "OG001", "value": "244.5", "spread": "70.1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2h-PMG at Week 78", "description": "Change from baseline was calculated by subtracting the baseline level from the Week 78 level.", "populationDescription": "Extension full analysis set population defined as all randomized participants who received at least one dose of extension study treatment, have baseline and at least one post-randomization observation for the analysis endpoint subsequent to at least one dose of extension study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline (Week 0) and Week 78", "groups": [{"id": "OG000", "title": "Omarigliptin 0.25 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG001", "title": "Omarigliptin 1 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG002", "title": "Omarigliptin 3 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG003", "title": "Omarigliptin 10 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG004", "title": "Omarigliptin 25 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG005", "title": "Placebo (Base)/Metformin (Extension)", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (Base) followed by pioglitazone 30 mg administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (Extension). Piogliatazone was removed by a protocol amendment and replaced with metformin starting dose 500 mg one daily up-titrated to 1000 mg twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "82"}, {"groupId": "OG004", "value": "70"}, {"groupId": "OG005", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-37.0", "lowerLimit": "-54.1", "upperLimit": "-20.0"}, {"groupId": "OG001", "value": "-21.3", "lowerLimit": "-38.2", "upperLimit": "-4.4"}, {"groupId": "OG002", "value": "-18.0", "lowerLimit": "-35.9", "upperLimit": "-0.1"}, {"groupId": "OG003", "value": "-27.6", "lowerLimit": "-46.3", "upperLimit": "-8.9"}, {"groupId": "OG004", "value": "-43.2", "lowerLimit": "-62.0", "upperLimit": "-24.4"}, {"groupId": "OG005", "value": "-40.3", "lowerLimit": "-58.1", "upperLimit": "-22.6"}]}]}]}, {"type": "SECONDARY", "title": "Mean FPG Level at Baseline of the Extension Period", "description": "Plasma FPG levels were measured at baseline (Week 0) for particiapnts who entered the extension period.", "populationDescription": "All participants who entered the extension period of the study with available FPG baseline data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline (Week 0)", "groups": [{"id": "OG000", "title": "Pooled Omarigliptin (Extension)", "description": "Participants received omarigliptin 25 mg once weekly for 66 weeks (extension period)"}, {"id": "OG001", "title": "Placebo/Metformin (Extension)", "description": "Participants who received matching placebo to omarigliptin during the base study, received pioglitazone 30 mg once daily and matching placebo to omarigliptin once weekly for 66 weeks (Extension period). Participants were switched from pioglitazone to metformin starting at 500 mg once daily and titrated up to 1000 mg twice a day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "405"}, {"groupId": "OG001", "value": "80"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "169.4", "spread": "41.7"}, {"groupId": "OG001", "value": "172.9", "spread": "43.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG Levels at Week 78", "description": "Change from baseline was calculated by subtracting the baseline level from the Week 78 level.", "populationDescription": "Extension full analysis set population defined as all randomized participants who received at least one dose of extension study treatment, have baseline and at least one post-randomization observation for the analysis endpoint subsequent to at least one dose of extension study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline (Week 0) and Week 78", "groups": [{"id": "OG000", "title": "Omarigliptin 0.25 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG001", "title": "Omarigliptin 1 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG002", "title": "Omarigliptin 3 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG003", "title": "Omarigliptin 10 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG004", "title": "Omarigliptin 25 mg (Base)/25 mg (Extension)", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (Base) followed by omarigliptin 25 mg once weekly for 66 weeks (Extension)"}, {"id": "OG005", "title": "Placebo (Base)/Metformin (Extension)", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (Base) followed by pioglitazone 30 mg administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (Extension). Piogliatazone was removed by a protocol amendment and replaced with metformin starting dose 500 mg one daily up-titrated to 1000 mg twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "82"}, {"groupId": "OG004", "value": "70"}, {"groupId": "OG005", "value": "80"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.4", "lowerLimit": "-22.4", "upperLimit": "7.6"}, {"groupId": "OG001", "value": "-11.3", "lowerLimit": "-25.0", "upperLimit": "2.5"}, {"groupId": "OG002", "value": "-2.0", "lowerLimit": "-17.1", "upperLimit": "13.1"}, {"groupId": "OG003", "value": "-10.0", "lowerLimit": "-25.0", "upperLimit": "5.0"}, {"groupId": "OG004", "value": "-0.7", "lowerLimit": "-16.7", "upperLimit": "15.3"}, {"groupId": "OG005", "value": "-19.6", "lowerLimit": "-34.1", "upperLimit": "-5.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 82 weeks (including 28 days following the last dose of study drug)", "description": "All participants as treated population. Serious AEs and non-serious AEs (NSAEs) include and exclude data after glycemic rescue, respectively. During the base period, 17 participants initiated glycemic rescue and were not included in the total number at risk for NSAEs during the extension period. MedDRA 15.1 was used for extension arms only.", "eventGroups": [{"id": "EG000", "title": "Omarigliptin 0.25 mg (Base)", "description": "Omarigliptin 0.25 mg administered once weekly for 12 weeks (base period)", "seriousNumAffected": 0, "seriousNumAtRisk": 113, "otherNumAffected": 6, "otherNumAtRisk": 113}, {"id": "EG001", "title": "Omarigliptin 1 mg (Base)", "description": "Omarigliptin 1 mg administered once weekly for 12 weeks (base period)", "seriousNumAffected": 1, "seriousNumAtRisk": 115, "otherNumAffected": 7, "otherNumAtRisk": 115}, {"id": "EG002", "title": "Omarigliptin 3 mg (Base)", "description": "Omarigliptin 3 mg administered once weekly for 12 weeks (base period)", "seriousNumAffected": 0, "seriousNumAtRisk": 114, "otherNumAffected": 4, "otherNumAtRisk": 114}, {"id": "EG003", "title": "Omarigliptin 10 mg (Base)", "description": "Omarigliptin 10 mg administered once weekly for 12 weeks (base period)", "seriousNumAffected": 2, "seriousNumAtRisk": 115, "otherNumAffected": 5, "otherNumAtRisk": 115}, {"id": "EG004", "title": "Omarigliptin 25 mg (Base)", "description": "Omarigliptin 25 mg administered once weekly for 12 weeks (base period)", "seriousNumAffected": 3, "seriousNumAtRisk": 114, "otherNumAffected": 7, "otherNumAtRisk": 114}, {"id": "EG005", "title": "Placebo (Base)", "description": "Matching placebo to omarigliptin administered once weekly for 12 weeks (base period)", "seriousNumAffected": 0, "seriousNumAtRisk": 113, "otherNumAffected": 6, "otherNumAtRisk": 113}, {"id": "EG006", "title": "Pooled Omarigliptin (Extension)", "description": "Participants received omarigliptin 25 mg once weekly for 66 weeks (extension period)", "seriousNumAffected": 28, "seriousNumAtRisk": 405, "otherNumAffected": 76, "otherNumAtRisk": 392}, {"id": "EG007", "title": "Placebo/Metformin (Extension)", "description": "Participants who received matching placebo to omarigliptin during the base study, received pioglitazone 30 mg once daily and matching placebo to omarigliptin once weekly for 66 weeks (Extension period). Participants were switched from pioglitazone to metformin starting at 500 mg once daily and titrated up to 1000 mg twice a day", "seriousNumAffected": 3, "seriousNumAtRisk": 80, "otherNumAffected": 10, "otherNumAtRisk": 76}], "seriousEvents": [{"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Tachyarrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Diabetic retinopathy", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Herpes zoster oticus", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Arthropod sting", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Meniscus lesion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Procedural complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 80}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Liposarcoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Prostate cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 3, "numAffected": 3, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Diabetic neuropathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Intraventricular haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 80}]}, {"term": "Subarachnoid haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 80}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Post procedural infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Trigger finger", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 405}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 80}]}], "otherEvents": [{"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 18, "numAffected": 13, "numAtRisk": 392}, {"groupId": "EG007", "numEvents": 4, "numAffected": 4, "numAtRisk": 76}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 6, "numAffected": 6, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 4, "numAffected": 4, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 52, "numAffected": 45, "numAtRisk": 392}, {"groupId": "EG007", "numEvents": 5, "numAffected": 4, "numAtRisk": 76}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1, 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 113}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 113}, {"groupId": "EG006", "numEvents": 49, "numAffected": 23, "numAtRisk": 392}, {"groupId": "EG007", "numEvents": 3, "numAffected": 3, "numAtRisk": 76}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Australia", "Chile", "Colombia", "Denmark", "Finland", "France", "Germany", "Hungary", "Japan", "Latvia", "Lithuania", "Malaysia", "Mexico", "New Zealand", "Peru", "Romania", "Serbia", "South Africa", "Spain", "Taiwan", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077205", "term": "Pioglitazone"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}